Sanofi, the French biotech company partnering with Regeneron in the global development and marketing of Zaltrap, made a third-quarter milestone payment of $50 million following the drug"™s approval in August for patients in the U.S. with metastatic colorectal cancer. Sanofi reported $8 million in net sales of Zaltrap in the third quarter. Regeneron"™s collaborator for Eylea, Bayer Healthcare, made a third-quarter milestone payment of $15 million for the drug"™s marketing approval in Japan. Editor's note: Updated 12:15 p.m. Oct. 29, 2012 with additional reporting by John Golden.